SAN DIEGO, May 25, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics ...

FREDERICTON, NEW BRUNSWICK--(Marketwired - Sept. 22, 2017) - Effective today Mr. Andrew Burgess has resigned from the Board of Trius Investments Inc. ("Trius") (TSX VENTURE:TRU) to pursue other ...

SAN DIEGO, April 11, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company has received official notification from the U.S. Patent and Trademark Office that ...

SAN DIEGO, March 25, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced top-line results from its ESTABLISH 2 Phase 3 clinical trial of tedizolid phosphate (TR-701) for ...

FREDERICTON, New Brunswick, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Trius Investments Inc. (TSXV: TRU) (“Trius” or the “Company”) is pleased to provide the following updates with respect to its mineral ...

In an effort to tap into the vast potential of the oceans as a source for novel medical treatments, the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense (DoD), has awarded ...

SAN DIEGO, Dec. 19, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. TSRX +10.54% announced today that tedizolid phosphate met the primary objective of non-inferiority for the efficacy outcome of ...

Trius Therapeutics added its name to the initial public offering queue on Friday, apparently undeterred by the abysmal performance of Omeros Corp., the first true biotech to go public in the current ...

Trius Therapeutics made headlines just over a year ago when the San Diego antibiotic developer raised $45.6 million in an initial public stock offering. Since then, the company has doubled in size as ...

Trius Lending Partners, a mid-Atlantic-focused private money lender for real estate investors, expanded its leadership team with the appointment of Eric Benzer, Esq. as director of business ...